Novo Nordisk’s Wegovy tablet launch attracts new wave of sufferers to GLP-1s

After years of making an attempt to shed pounds “the appropriate means,” Jane Zuckerman realized that “placing within the work simply wasn’t sufficient.” 

Zuckerman, a 32-year-old knowledge analyst based mostly in Washington, D.C., stated she misplaced 90 kilos in school and spent years biking via nutritionists, remedy and strict routines — solely to search out herself at her heaviest after the pandemic, at 270 kilos. 

Zuckerman stated GLP-1 injections have been out of the query, as a result of she’s afraid of needles. However when the primary GLP-1 tablet for weight problems turned obtainable in early January, Zuckerman known as her physician instantly, she stated. 

Virtually a month after beginning Novo Nordisk‘s new Wegovy tablet shortly after it launched, she stated, she had misplaced round 11 kilos.

Zuckerman is amongst tens of 1000’s of sufferers who drove an explosive demand for prescriptions for Novo’s tablet simply three months into its launch. A lot of them share a typical thread: That they had lengthy held off on utilizing GLP-1s as a consequence of limitations comparable to excessive out-of-pocket prices for injections or a worry of needles.

That is one of many earliest takeaways from the rollout: Novo’s tablet seems to be increasing the weight problems therapy market, largely drawing in new sufferers moderately than changing current ones from injections. CNBC spoke with 5 U.S. sufferers who not too long ago began the tablet following its launch, all of whom stated they haven’t beforehand taken branded GLP-1 injections.

But it surely’s early days for the tablet. Many sufferers have but to achieve larger doses of the drug, and their experiences differ. It can take extra time to find out how efficient the tablet is in supporting sufferers’ long-term weight reduction journeys, whether or not it helps maintain customers on GLP-1s for longer than injections do and whether or not demand for Novo’s product will maintain within the face of recent competitors from Eli Lilly. 

Novo has a head begin within the tablet area over Lilly, which simply received U.S. approval of its personal GLP-1 drug for weight problems final week. Analysts beforehand instructed CNBC they nonetheless count on that rival tablet, known as Foundayo, to seize a phase of the market, partly as a result of it lacks the dietary restrictions that include Novo’s oral drug. 

Nonetheless, the Wegovy tablet seems to have had essentially the most explosive launch of a GLP-1 product but. The most recent quantity that Novo disclosed in February is that greater than 600,000 prescriptions had been written since its launch, together with for greater than 3,000 sufferers within the first week.

Analysts at BMO Capital Markets attributed among the early uptake to an “enticing” entry value of $149 per 30 days and its connection to the well-known Wegovy model. The tablet carries one of many lowest money costs for a GLP-1 remedy, starting from $149 to $299 per 30 days, relying on the dose.

Even so, the tablet’s launch has carried out little to spice up Novo’s inventory value, because the Danish drugmaker is struggling to win again market share from Lilly within the broader weight problems house and persuade traders that its drug pipeline can assist it develop past its current merchandise.

Novo is predicted to report first-quarter gross sales, which is able to embrace the tablet for the primary time, in Might. However gross sales of the general Wegovy portfolio are anticipated to extend from $13.5 billion in 2026 to $18.9 billion in 2031, with the tablet contributing $2.76 billion, based on a March GlobalData report.  

The Wegovy tablet is attracting sufferers with a worry of needles, which is estimated to have an effect on as much as 25% of U.S. adults. However the drug can be another for individuals who have had issue accessing branded GLP-1 injections or different medicines. 

“There are a handful of sufferers that do not wish to be stung by the needle within the case of a vial and syringe, or stung by the value,” Jamey Millar, Novo’s head of U.S. operations, instructed CNBC in an interview final week. “We’re interesting to each.” 

Dr. Eduardo Grunvald, medical director of the UC San Diego Well being Middle for Superior Weight Administration, stated the principle purpose he is prescribed the Wegovy tablet to some sufferers is price, since its money costs are barely decrease than these of injections. However Grunvald stated general, weight problems drugs specialists like him will nonetheless be inclined to prescribe injections over oral medicine, partly as a result of the pictures are more practical. 

Price was a deciding issue for Amy Sawyer-Williams, who works at a theater firm in Raleigh, North Carolina, and has gestational diabetes. In 2023, a couple of years after her son was born, she stated, she started creating prediabetes and met the standards for weight problems. She stated she would have began utilizing GLP-1 injections sooner, however her insurance coverage wouldn’t cowl them for her. 

That was lengthy earlier than Novo and Lilly slashed the money costs of their weight problems and diabetes injections. 

The record costs of their pictures are roughly $1,000 per 30 days earlier than insurance coverage and different rebates, or reductions for cash-paying sufferers — a sum that has lengthy prevented many others from beginning and staying on therapy. Novo has dedicated to slicing the month-to-month record costs of its medicine within the U.S. by as much as 50%, however that change will not go into impact till 2027. 

Excessive costs additionally shut Sawyer-Williams out from taking the branded weight administration therapy Contrave, pushing her to mix two generic medicines to imitate the drug’s results, she stated. However earlier this 12 months, she stated, her endocrinologist really helpful the Wegovy tablet, partly as a consequence of its decrease $149 per 30 days pricing for the beginning dose. 

Sawyer-Williams turned the primary affected person at her physician’s apply and native Walgreens to take the tablet, beginning in mid-January, she stated. 

Some Wegovy tablet customers are sufferers who wished to modify over from injections, stated Dr. Heather Hofflich, a doctor and endocrinologist at UCSD Well being. She stated she’s prescribed the tablet for some individuals whose insurance coverage stopped masking the injections however who wish to proceed therapy. 

Hofflich stated she has additionally prescribed the oral drug to sufferers who misplaced weight initially on a shot however at the moment are making an attempt the tablet to keep up that progress. 

Whereas it is nonetheless early, some sufferers stated they’re already benefiting from taking Novo’s drug. 

Zuckerman was initially skeptical of how efficient the product can be, as a result of it is an oral treatment. However, she stated, “I swear I felt the influence on the primary day,” notably decreased urge for food and disinterest in meals. 

“Issues that used to offer me enjoyment, or issues I used to binge on, they only do not style nearly as good anymore, and I simply do not see the purpose in consuming them, truthfully,” Zuckerman stated, itemizing espresso, cheese, bread and fries, amongst different meals and drinks. 

She stated she handled nausea — a typical facet impact of the GLP-1 class — however that turned extra manageable after the primary two weeks on the tablet.

Zuckerman additionally stated what issues greater than the load loss or meals urges is how she feels: “My garments are looser, I’ve extra vitality, I genuinely really feel higher.” 

Cherie Marcus, 72, a retired cloth designer and theater editor based mostly in Brooklyn, stated she’s additionally seen gradual progress — even on the bottom 1.5-milligram dose of the drug. She stated that during the last 30 years, after her daughter was born, she’s gained weight and seen her hemoglobin A1c — a key measure of blood sugar ranges — creep up. 

Marcus stated she began the tablet on Jan. 24, and has misplaced a few pound every week whereas taking the bottom dose for seven weeks. Sufferers sometimes enhance their dosage after a month, however Marcus stated she’s nonetheless taking the bottom power as of early April. 

However her weight has “leveled off” over the previous few weeks, she stated, so she is going to seemingly transfer to a better dose if she stops losing a few pounds fully. Marcus sees herself taking the tablet long run, with a objective of shedding round 30 kilos. 

Novo’s Millar final week stated some sufferers might begin on decrease doses and “be completely fantastic with that,” hitting their very own private targets for weight reduction. However the firm is monitoring what number of sufferers enhance to larger doses of the drug, notably the 9-mg and 25-mg variations.  

Courtney Kim, a stay-at-home mother based mostly in Pittsburgh, is among the many sufferers taking the Wegovy tablet who’ve but to expertise notable uncomfortable side effects. 

Whereas she would not qualify as overweight, Kim stated, the “weight would simply not come off” after she had her three kids. She began the tablet round mid-February after struggling to shed pounds with using different prescription medicines and dietary supplements, she stated. 

Kim began at a weight of roughly 158 kilos and has up to now misplaced practically 7 kilos on the tablet, she stated. She not too long ago began the 4-mg dose of the drug. 

“It is truly working, and I am shocked that the load is definitely like coming off and staying off,” Kim stated. “Thus far I’ve had a optimistic expertise.”

The early expertise with the tablet hasn’t been clean for everybody. UCSD’s Hofflich stated she had one affected person who couldn’t tolerate the tablet as a consequence of its gastrointestinal uncomfortable side effects, which is a typical challenge with the injections, as nicely. 

One other affected person needed to change to an injection as a result of the tablet’s dietary restrictions — which contain taking it with a small quantity of water and ready half-hour earlier than consuming or ingesting — didn’t match into their life-style, Hofflich stated. Two sufferers who have not seen progress on larger doses of the tablet are switching to injections, she stated. 

Hofflich stated different sufferers who have not seen progress on decrease doses are beginning to take larger doses to see if that may make a distinction. 

That features a affected person based mostly in New Hampshire named Amy, who stated she started taking the Wegovy tablet in early February. She requested CNBC to not use her final title, for privateness causes.

Amy stated she initially thought of a branded GLP-1 therapy two years in the past after her weight crept as much as 190 kilos, however her physician stated her insurance coverage would not cowl it. Amy then turned to cheaper, unapproved compounded variations of GLP-1s for a 12 months and misplaced 30 kilos earlier than stopping in November. 

She stated the 2 lowest doses of the Wegovy tablet — 1.5 mg and 4 mg — “did completely nothing for me” over two months. 

Novo’s money reductions allowed Amy to pay roughly $300 complete for a month’s value of every dose, however she stated she feels “annoyed” that she nonetheless feels hungry and has seen no modifications other than uncomfortable side effects together with constipation. Amy stated her weight is “hovering” round 170 kilos.

“It simply sort of felt like a waste of time,” she stated. 

Amy stated she plans to begin the 9-mg dose of the tablet quickly, hoping that she’ll start to see the advantages of therapy. She stated if that does not work, she’ll focus on along with her physician whether or not to attempt the best dose, 25 mg, or probably flip again to compounded GLP-1s. 

In the meantime, Sawyer-Williams is restarting the bottom dose of the tablet after pausing the drug as a consequence of gastrointestinal uncomfortable side effects. She stated she was nervous about beginning the tablet, as a result of she’s all the time had a delicate abdomen. 

Throughout her first three weeks on the 1.5-mg dose of the oral drug, she didn’t discover any weight reduction, however skilled nausea if she did not eat, Sawyer-Williams stated. She began to really feel much less desirous about meals by her fourth week, she stated, however started taking the subsequent dose, 4 mg, shortly after.  

On the seventh day of taking that dose, Sawyer-Williams stated, she skilled “the worst” nausea, vomiting and dehydration, which induced her to cease therapy. 

“I want I had simply stayed on the 1.5” dose, she stated. “I used to be actually, actually sick. Even after I give up the tablet, I simply could not maintain down water.”

Sawyer-Williams began at a weight of 177 kilos and misplaced 5 kilos general after taking the drug, she stated. She’s been off therapy for a couple of weeks, however began the bottom dose of the tablet as of early April with new habits, together with staying hydrated and beginning to carry weights, she stated.

“We will simply must hope that it is sufficient to assist me,” she stated, referring to the bottom dose. 

Dr. Andrea Traina, Novo’s weight problems medical director, really helpful that sufferers who’re fighting uncomfortable side effects speak to their health-care supplier about methods to mitigate them. For instance, she stated some individuals might profit from staying on a decrease dose till they tolerate the drug higher earlier than growing to a better dosage.

“Treating weight problems, identical to most persistent illnesses, is sort of a marathon, not a dash,” Traina stated in an interview. “So including an additional month or two to assist with tolerability upfront can assist with sort of long-term success.”

A number of questions stay in regards to the long-term use of the tablet, particularly on larger doses, and it might not be the very best weight problems therapy for each affected person, specialists stated. 

Traina stated every affected person has a person response, they usually might reply nicely above or nicely under common when it comes to weight reduction and uncomfortable side effects. That may be tied to their genetics, atmosphere or dietary habits, and experiences can differ barely throughout sure populations and age teams, she stated.

“It’s totally powerful to know why one affected person’s responding to one thing and one other is not,” Traina stated, including that it is “one of many many advantages of getting a number of therapy choices obtainable.”

Having an oral choice at decrease money costs that “could be attainable for a bigger inhabitants is an excellent factor, to assist us remedy or alleviate this persistent illness state,” stated UCSD’s Hofflich. 

She stated within the coming months, notably with the rollout of Lilly’s new drug, “we’ll have many extra tales and outcomes” of drugs to guage, permitting for clearer comparisons between the 2 drugs in addition to injections.

Sufferers comparable to Zuckerman might provide an early glimpse of those that stand to profit most from the tablet — and the circumstances the place it resonates.

“I used to be on this boat of seeing the tablet as dishonest and feeling like I needed to lose the load the laborious means,” she stated. “However that does not work for everyone, and finally I received to the purpose the place I used to be like, do I wish to be cussed and check out to do that the ‘proper means,’ or do I wish to die from being overweight?”

“Leaping on the chance to [take] the tablet at this stage in my life was the appropriate determination,” Zuckerman stated.